Artificial Intelligence

The strategic acquisition combines computer vision with spatial intelligence, aiming to make advanced in-store analytics an accessible, essential tool for retailers.

NCR Voyix is launching a new AI-driven, microservices-based platform designed to help restaurants combat labor shortages and meet rising customer expectations.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With a major investment from Santé Ventures, Brado AI is deploying conversational AI to guide patients and ease provider burdens. Here’s what it means.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

A new partnership makes Eli Lilly's powerful AI models available to smaller firms via Revvity's platform, aiming to accelerate innovation with federated learning.

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

As Mammoth Biosciences preps for JPM, its ultracompact CRISPR tech aims to redefine in vivo gene therapy, promising cures for diseases beyond the liver.

Lightspeed's new conversational AI acts as a business partner for retailers and restaurants, turning complex data into simple answers to boost performance.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.